The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

Launched by UNIVERSITY OF CHICAGO · Jan 19, 2011

Keywords

ClinConnect Summary

The 1200 Patients Project is a clinical trial taking place at the University of Chicago that aims to study how genetic testing can help doctors choose the right medications for patients. The trial will collect DNA samples from patients who are receiving regular outpatient care. By analyzing these samples, researchers will look for genetic differences that may affect how patients respond to certain medications or experience side effects. The goal is to see if knowing this genetic information can help doctors make better treatment decisions for their patients.

To be eligible for this study, participants need to be at least 18 years old and currently receiving care at the University of Chicago. They should also be taking at least one prescription medication or be expected to need one soon. The study is especially looking for patients with specific conditions like heart disease, inflammatory bowel diseases, autoimmune diseases, and others. Participants can expect to provide a DNA sample and have their results shared with their doctor, who may use this information to improve their treatment. It's important to note that patients who have serious health issues or are considering organ transplants may not be able to join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial
• • Life expectancy of at least 3 years
• • Must be 18 years or older
• • Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years
• * Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to:
• • Patients requiring specialized cardiology care
• • Patients with inflammatory bowel diseases
• • Patients with systemic autoimmune or inflammatory diseases
• • Patients requiring long-term oral anticoagulation
• • Patients with hepatitis C
• • Patients with non-metastatic cancer
• Exclusion Criteria:
• • Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years.
• • Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
• • Inability to understand and give informed consent to participate.